Objective: To investigate the co-expression of drug resistance- and apoptosis-related genes of cisplatin (CDDP)-selected lung adenocarcinoma cell line A 549 DDP for compared to the parental cell line A549, and reverse...Objective: To investigate the co-expression of drug resistance- and apoptosis-related genes of cisplatin (CDDP)-selected lung adenocarcinoma cell line A 549 DDP for compared to the parental cell line A549, and reverse of drug resistance by antisense s-oligodeoxynucleotides (S-ODNs) of differentially expressed genes. Methods: Sense and antisense S-ODN were transferred into A 549 DDP cells by lipofectin. The expression of drug resistance and apoptosis related genes was examined by RT-PCR, immunocytochemistry and flow cytometry, respectively. Apoptostic cells were identified by DNA electrophoresis and terminal deoxynucleotidyl transferase (TdT)-mediated biotin dUTP nick end-labeling(TUNEL). Drug resistance of tumor cells was detected by a cell viability (MTT) assay. Results: The expression of bcl-2 was positive and that of multidrug resistance-associated protein (MRP) at mRNA and protein level was increased in A 549 DDP compared to A549 cells. MDR1, c-myc and topoisomeras II (TOPO II) were similarly co-expressed in two cell lines. Both cell lines were negative for c-erbB-2 expression. In A 549 DDP cells, the expression of bcl-2 and MRP was significantly inhibited by their respective antisense S-ODNs. Antisense S-ODNs could also decrease significantly drug resistance of A 549 DDP cells to CDDP by promoting cell apoptosis. Conclusion: Both intrinsic and acquired drug resistance were involved in co-expression of multiple MDR-related genes in lung adenocarcinoma. Cooperation of bcl-2 and MRP genes appeared to play an important action to confer the resistance of A 549 DDP cells to CDDP. Their antisense S-ODNs are responsible for the decrease of drug resistance of this cell line by promoting apoptosis.展开更多
Objective： The aim of the study was to compare efficacies and safeties of 2 different treatments of whole brain radiotherapy （WBRT） sequential or concomitant Vm26/DDP for small cell lung cancer （SCLC） patients wi...Objective： The aim of the study was to compare efficacies and safeties of 2 different treatments of whole brain radiotherapy （WBRT） sequential or concomitant Vm26/DDP for small cell lung cancer （SCLC） patients with brain metastases. Methods： A total of 39 patients were randomly divided into sequential chemoradiotherapy regime （A group, 20 patients） and concomitant chemoradiotherapy regime （B group, 19 patients）. The close of WBRT was 36 Gy in 18-20 fractions, chemotherapy of Vm26/DDP regimen with teniposide 60 mg/m^2 on dl to d3 and cisplatin 20 mg/m^2 on dl to d5, repeating every 3 weeks. The response was evaluated after WBRT and 2 cycles of chemotherapy. Results： Total response rates of A and B groups were 70.0% and 78.9% respectively （P = 0.520）. The median survival was 11 months in A group and 10 months in B group. Six, twelve and eighteen months cumulative survival rates of A and B groups were 75.0%, 42.5%, 26.2%, and 81.6%, 26.4%, 10.5%, respectively （χ^2 = 0.383, P 〉 0.05）. Response rate and the number of brain metastases were independent prognostic factors. Conclusion： Both sequential and concomitant chemoradiotherapy groups are effective, and the main toxicity with myelosuppression is tolerable after therapy. It can be applied firstly and effectively to the SCLC patients with brain metastases in clinic.展开更多
Objective： Recombinant human Endostatin （rh-Endostatin, YH-16） can reverse cisplatin resistance in A549/DDP cells. However, the possible effect of rh-Endostatin in reversing DDP-resistance in A549/DDP cells and the...Objective： Recombinant human Endostatin （rh-Endostatin, YH-16） can reverse cisplatin resistance in A549/DDP cells. However, the possible effect of rh-Endostatin in reversing DDP-resistance in A549/DDP cells and the mechanism are needed to be investigated. Methods： Lung adenocarcinoma cell line A549 and its DDP-resistant cell line A549/DDP were treated with DDP and/or recombinant human Endostatin. Difference in drug resistance was analyzed between different regi- mens and between different cell lines after a 72 h-treatment in vitro. And below the non-cytotoxic concentration of rh-End- ostatin, the possibility of rh-Endostatin in reversing DDP-resistance in A549/DDP was evaluated. The resistance protein which was detected in the study included P glycoprotein （P-gp） and topoisomerase II （Topo-II）. Results： Rh-Endostatin below 400 IJg/mL showed no cytotoxicity in either A549 or A549/DDP after 72 h-treatment with it. The inhibited concentration of 50% （IC50） observed for DDP was （0.79 _＋ 0.05） IJg/mL in A549 and （13.2 ＋ 1.1） in A549/DDP respectively. IC50 was reduced to 2.57 ＋ 0.05 #g/mL in A549/DDP treated by rh-Endostatin below the non-cytotoxic concentrations in combination with DDP, with a reversal fold （RF） of 5.14 and a relative reversal rate of 85.6%. Apoptotic rates were 2.01%, 13.47% and 29.26% re- spectively for cells treated with rh-Endostain, DDP, and the combination. The rate of the A549/DDP control group was 0.99%. The expression level of P-gp or Topo-II was higher in A549/DDP cells than in A549 cells. Rh-Endostatin may partially reverse DDP-resistance in A549/DDP cells in vitro, with a probable mechanism related to lowering expression of P-gp and Topo-II. Conclusien： Rh-Endostatin of non-cytotoxic dose partially reversed cisptatin resistance in cisplatin-resistant human lung adenocarcinoma cell line A549/DDP. Rh-Endostatin reversed the resistance of A549/DDP cells to DDP, which may be related to decreased protein expression of P-gp and Topo-II in A549/DDP cells.展开更多
背景白藜芦醇不仅具有抗肿瘤作用,其还能增强多种化疗药物的化疗敏感性,但其对食管癌耐药细胞的顺铂敏感性的作用尚不清楚.目的探讨白藜芦醇逆转食管癌细胞Eca109/DDP的耐药效应并从铁死亡的角度分析其潜在的作用机制.方法采用MTT法确...背景白藜芦醇不仅具有抗肿瘤作用,其还能增强多种化疗药物的化疗敏感性,但其对食管癌耐药细胞的顺铂敏感性的作用尚不清楚.目的探讨白藜芦醇逆转食管癌细胞Eca109/DDP的耐药效应并从铁死亡的角度分析其潜在的作用机制.方法采用MTT法确定白藜芦醇和顺铂的最佳作用时间和浓度;检测细胞增殖、细胞内丙二醛(malondialdehyde,MDA)、谷胱甘肽(glutathione,GSH)、活性氧(reactive oxygen species,ROS)及铁离子的水平;Western blot检测铁死亡相关调控因子酰基辅酶A合成酶长链家族成员4(acyl coenzyme A synthetase long chain family member 4,ACSL4)、铁蛋白重链(ferritin heavy chain,FTH)、谷胱甘肽过氧化物酶4(glutathione peroxidase 4,GPX4)和肿瘤蛋白53(tumor protein 53,P53)的蛋白表达情况.结果MTT检测结果显示,相较于单用顺铂,联用白藜芦醇对Eca109/DDP细胞的生长抑制作用较为显著(P<0.05).此外,白藜芦醇和顺铂联用可显著降低Eca109/DDP细胞克隆形成数(P<0.05),增加细胞内铁离子、MDA和ROS水平(P<0.05),降低GSH水平(P<0.05).铁死亡抑制剂(ferrostatin-1,Fer-1)和铁离子螯合剂(deferoxamine,DFO)可部分逆转白藜芦醇对细胞增殖的抑制作用(P<0.05).Western blot的结果显示相较于其他组,白藜芦醇和顺铂联用组的FTH和GPX4的蛋白表达显著降低(P<0.05),而ACSL4和P53的蛋白表达显著增加(P<0.05).结论白藜芦醇可通过铁死亡抑制Eca109/DDP细胞的增殖并逆转顺铂耐药.展开更多
目的:探讨叉头框转录因子M1(FoxM1)对人宫颈癌顺铂耐药株Hela/DDP增殖、侵袭、凋亡的影响及其机制。方法:将Hela/DDP细胞分为空白组(常规培养,不予任何处理)、正常对照(NC)组(转染空白干扰质粒)、低表达组和过表达组。低表达组转染siRNA...目的:探讨叉头框转录因子M1(FoxM1)对人宫颈癌顺铂耐药株Hela/DDP增殖、侵袭、凋亡的影响及其机制。方法:将Hela/DDP细胞分为空白组(常规培养,不予任何处理)、正常对照(NC)组(转染空白干扰质粒)、低表达组和过表达组。低表达组转染siRNA-FoxM1下调Hela/DDP细胞中FoxM1表达,过表达组转染pcDNA3.1-FoxM1上调Hela/DDP细胞中FoxM1表达。采用RT-qPCR法检测FoxM1 m RNA表达水平,CCK-8检测细胞活力,流式细胞仪检测细胞凋亡,Transwell小室检测细胞侵袭能力。结果:FoxM1 mRNA在Hela细胞中的表达水平低于Hela/DDP细胞(P<0.05)。空白组与NC组中FoxM1 mRNA、增殖率、凋亡率、侵袭细胞数及HSP70、S100A9蛋白表达水平比较,差异均无统计学意义(P>0.05)。与空白组比较,低表达组细胞活力和侵袭能力及FoxM1 mRNA、HSP70蛋白表达水平降低,凋亡率和S100A9蛋白表达水平升高(P<0.05),与空白组比较,过表达组细胞活力和侵袭能力及FoxM1 m RNA、HSP70蛋白表达水平升高,凋亡率和S100A9蛋白表达水平降低(P<0.05)。与低表达组比较,过表达组细胞活力和侵袭能力及FoxM1 mRNA、HSP70蛋白表达水平升高,凋亡率和S100A9蛋白表达水平降低(P<0.05)。结论:下调FoxM1表达可抑制HSP70表达,促进S100A9表达,调控宫颈癌细胞恶性行为,从而提高宫颈癌顺铂耐药细胞株对顺铂化疗的敏感性。展开更多
This work summarizes the structure and operating features of a high-performance 3-stage dual-delay-path (DDP) voltage-controlled ring oscillator (VCRO) with self-biased delay cells for Phase-Locked Loop (PLL) structur...This work summarizes the structure and operating features of a high-performance 3-stage dual-delay-path (DDP) voltage-controlled ring oscillator (VCRO) with self-biased delay cells for Phase-Locked Loop (PLL) structurebased clock generation and digital system driving. For a voltage supply V<sub>DD</sub> = 1.8 V, the resulting set of performance parameters include power consumption P<sub><sub></sub>DC</sub> = 4.68 mW and phase noise PN@1MHz = -107.8 dBc/Hz. From the trade-off involving P<sub>DC</sub> and PN, a system level high performance is obtained considering a reference figure-of-merit ( FoM = -224 dBc/Hz ). Implemented at schematic level by applying CMOS-based technology (UMC L180), the proposed VCRO was designed at Cadence environment and optimized at MunEDA WiCkeD tool.展开更多
基金the Grant from Beijing Natural Science Foundation (No.7992005)and a Grantfrom Postdoctoral Foundation of National Committee of E
文摘Objective: To investigate the co-expression of drug resistance- and apoptosis-related genes of cisplatin (CDDP)-selected lung adenocarcinoma cell line A 549 DDP for compared to the parental cell line A549, and reverse of drug resistance by antisense s-oligodeoxynucleotides (S-ODNs) of differentially expressed genes. Methods: Sense and antisense S-ODN were transferred into A 549 DDP cells by lipofectin. The expression of drug resistance and apoptosis related genes was examined by RT-PCR, immunocytochemistry and flow cytometry, respectively. Apoptostic cells were identified by DNA electrophoresis and terminal deoxynucleotidyl transferase (TdT)-mediated biotin dUTP nick end-labeling(TUNEL). Drug resistance of tumor cells was detected by a cell viability (MTT) assay. Results: The expression of bcl-2 was positive and that of multidrug resistance-associated protein (MRP) at mRNA and protein level was increased in A 549 DDP compared to A549 cells. MDR1, c-myc and topoisomeras II (TOPO II) were similarly co-expressed in two cell lines. Both cell lines were negative for c-erbB-2 expression. In A 549 DDP cells, the expression of bcl-2 and MRP was significantly inhibited by their respective antisense S-ODNs. Antisense S-ODNs could also decrease significantly drug resistance of A 549 DDP cells to CDDP by promoting cell apoptosis. Conclusion: Both intrinsic and acquired drug resistance were involved in co-expression of multiple MDR-related genes in lung adenocarcinoma. Cooperation of bcl-2 and MRP genes appeared to play an important action to confer the resistance of A 549 DDP cells to CDDP. Their antisense S-ODNs are responsible for the decrease of drug resistance of this cell line by promoting apoptosis.
文摘Objective： The aim of the study was to compare efficacies and safeties of 2 different treatments of whole brain radiotherapy （WBRT） sequential or concomitant Vm26/DDP for small cell lung cancer （SCLC） patients with brain metastases. Methods： A total of 39 patients were randomly divided into sequential chemoradiotherapy regime （A group, 20 patients） and concomitant chemoradiotherapy regime （B group, 19 patients）. The close of WBRT was 36 Gy in 18-20 fractions, chemotherapy of Vm26/DDP regimen with teniposide 60 mg/m^2 on dl to d3 and cisplatin 20 mg/m^2 on dl to d5, repeating every 3 weeks. The response was evaluated after WBRT and 2 cycles of chemotherapy. Results： Total response rates of A and B groups were 70.0% and 78.9% respectively （P = 0.520）. The median survival was 11 months in A group and 10 months in B group. Six, twelve and eighteen months cumulative survival rates of A and B groups were 75.0%, 42.5%, 26.2%, and 81.6%, 26.4%, 10.5%, respectively （χ^2 = 0.383, P 〉 0.05）. Response rate and the number of brain metastases were independent prognostic factors. Conclusion： Both sequential and concomitant chemoradiotherapy groups are effective, and the main toxicity with myelosuppression is tolerable after therapy. It can be applied firstly and effectively to the SCLC patients with brain metastases in clinic.
基金Supported by a grant from the Natural Science Foundation of Liaoning Province(No.201202043)
文摘Objective： Recombinant human Endostatin （rh-Endostatin, YH-16） can reverse cisplatin resistance in A549/DDP cells. However, the possible effect of rh-Endostatin in reversing DDP-resistance in A549/DDP cells and the mechanism are needed to be investigated. Methods： Lung adenocarcinoma cell line A549 and its DDP-resistant cell line A549/DDP were treated with DDP and/or recombinant human Endostatin. Difference in drug resistance was analyzed between different regi- mens and between different cell lines after a 72 h-treatment in vitro. And below the non-cytotoxic concentration of rh-End- ostatin, the possibility of rh-Endostatin in reversing DDP-resistance in A549/DDP was evaluated. The resistance protein which was detected in the study included P glycoprotein （P-gp） and topoisomerase II （Topo-II）. Results： Rh-Endostatin below 400 IJg/mL showed no cytotoxicity in either A549 or A549/DDP after 72 h-treatment with it. The inhibited concentration of 50% （IC50） observed for DDP was （0.79 _＋ 0.05） IJg/mL in A549 and （13.2 ＋ 1.1） in A549/DDP respectively. IC50 was reduced to 2.57 ＋ 0.05 #g/mL in A549/DDP treated by rh-Endostatin below the non-cytotoxic concentrations in combination with DDP, with a reversal fold （RF） of 5.14 and a relative reversal rate of 85.6%. Apoptotic rates were 2.01%, 13.47% and 29.26% re- spectively for cells treated with rh-Endostain, DDP, and the combination. The rate of the A549/DDP control group was 0.99%. The expression level of P-gp or Topo-II was higher in A549/DDP cells than in A549 cells. Rh-Endostatin may partially reverse DDP-resistance in A549/DDP cells in vitro, with a probable mechanism related to lowering expression of P-gp and Topo-II. Conclusien： Rh-Endostatin of non-cytotoxic dose partially reversed cisptatin resistance in cisplatin-resistant human lung adenocarcinoma cell line A549/DDP. Rh-Endostatin reversed the resistance of A549/DDP cells to DDP, which may be related to decreased protein expression of P-gp and Topo-II in A549/DDP cells.
文摘背景白藜芦醇不仅具有抗肿瘤作用,其还能增强多种化疗药物的化疗敏感性,但其对食管癌耐药细胞的顺铂敏感性的作用尚不清楚.目的探讨白藜芦醇逆转食管癌细胞Eca109/DDP的耐药效应并从铁死亡的角度分析其潜在的作用机制.方法采用MTT法确定白藜芦醇和顺铂的最佳作用时间和浓度;检测细胞增殖、细胞内丙二醛(malondialdehyde,MDA)、谷胱甘肽(glutathione,GSH)、活性氧(reactive oxygen species,ROS)及铁离子的水平;Western blot检测铁死亡相关调控因子酰基辅酶A合成酶长链家族成员4(acyl coenzyme A synthetase long chain family member 4,ACSL4)、铁蛋白重链(ferritin heavy chain,FTH)、谷胱甘肽过氧化物酶4(glutathione peroxidase 4,GPX4)和肿瘤蛋白53(tumor protein 53,P53)的蛋白表达情况.结果MTT检测结果显示,相较于单用顺铂,联用白藜芦醇对Eca109/DDP细胞的生长抑制作用较为显著(P<0.05).此外,白藜芦醇和顺铂联用可显著降低Eca109/DDP细胞克隆形成数(P<0.05),增加细胞内铁离子、MDA和ROS水平(P<0.05),降低GSH水平(P<0.05).铁死亡抑制剂(ferrostatin-1,Fer-1)和铁离子螯合剂(deferoxamine,DFO)可部分逆转白藜芦醇对细胞增殖的抑制作用(P<0.05).Western blot的结果显示相较于其他组,白藜芦醇和顺铂联用组的FTH和GPX4的蛋白表达显著降低(P<0.05),而ACSL4和P53的蛋白表达显著增加(P<0.05).结论白藜芦醇可通过铁死亡抑制Eca109/DDP细胞的增殖并逆转顺铂耐药.
文摘目的:探讨叉头框转录因子M1(FoxM1)对人宫颈癌顺铂耐药株Hela/DDP增殖、侵袭、凋亡的影响及其机制。方法:将Hela/DDP细胞分为空白组(常规培养,不予任何处理)、正常对照(NC)组(转染空白干扰质粒)、低表达组和过表达组。低表达组转染siRNA-FoxM1下调Hela/DDP细胞中FoxM1表达,过表达组转染pcDNA3.1-FoxM1上调Hela/DDP细胞中FoxM1表达。采用RT-qPCR法检测FoxM1 m RNA表达水平,CCK-8检测细胞活力,流式细胞仪检测细胞凋亡,Transwell小室检测细胞侵袭能力。结果:FoxM1 mRNA在Hela细胞中的表达水平低于Hela/DDP细胞(P<0.05)。空白组与NC组中FoxM1 mRNA、增殖率、凋亡率、侵袭细胞数及HSP70、S100A9蛋白表达水平比较,差异均无统计学意义(P>0.05)。与空白组比较,低表达组细胞活力和侵袭能力及FoxM1 mRNA、HSP70蛋白表达水平降低,凋亡率和S100A9蛋白表达水平升高(P<0.05),与空白组比较,过表达组细胞活力和侵袭能力及FoxM1 m RNA、HSP70蛋白表达水平升高,凋亡率和S100A9蛋白表达水平降低(P<0.05)。与低表达组比较,过表达组细胞活力和侵袭能力及FoxM1 mRNA、HSP70蛋白表达水平升高,凋亡率和S100A9蛋白表达水平降低(P<0.05)。结论:下调FoxM1表达可抑制HSP70表达,促进S100A9表达,调控宫颈癌细胞恶性行为,从而提高宫颈癌顺铂耐药细胞株对顺铂化疗的敏感性。
文摘This work summarizes the structure and operating features of a high-performance 3-stage dual-delay-path (DDP) voltage-controlled ring oscillator (VCRO) with self-biased delay cells for Phase-Locked Loop (PLL) structurebased clock generation and digital system driving. For a voltage supply V<sub>DD</sub> = 1.8 V, the resulting set of performance parameters include power consumption P<sub><sub></sub>DC</sub> = 4.68 mW and phase noise PN@1MHz = -107.8 dBc/Hz. From the trade-off involving P<sub>DC</sub> and PN, a system level high performance is obtained considering a reference figure-of-merit ( FoM = -224 dBc/Hz ). Implemented at schematic level by applying CMOS-based technology (UMC L180), the proposed VCRO was designed at Cadence environment and optimized at MunEDA WiCkeD tool.
